
Sign up to save your podcasts
Or


Credits: 0.25 AMA PRA Category 1 Credit™
Overview: The obesity epidemic has fueled a demand for weight loss medications. Trials have directly compared medications—specifically glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—with a recent study doing just that. Tune in as we explore the evidence comparing semaglutide and tirzepatide for weight loss outcomes up to 1 year.
Episode resource links:
Guest: Alan M. Ehrlich, MD, FAAFP
Thoughts? Suggestions? Email us at [email protected]
By Pri-Med4.6
242242 ratings
Credits: 0.25 AMA PRA Category 1 Credit™
Overview: The obesity epidemic has fueled a demand for weight loss medications. Trials have directly compared medications—specifically glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—with a recent study doing just that. Tune in as we explore the evidence comparing semaglutide and tirzepatide for weight loss outcomes up to 1 year.
Episode resource links:
Guest: Alan M. Ehrlich, MD, FAAFP
Thoughts? Suggestions? Email us at [email protected]

138 Listeners

694 Listeners

498 Listeners

294 Listeners

299 Listeners

3,361 Listeners

1,145 Listeners

730 Listeners

191 Listeners

95 Listeners

515 Listeners

369 Listeners

247 Listeners

375 Listeners

318 Listeners